Subscribe
Models
Our Products
Featured Catalog
Humanized Mouse Models
Tool Mice
Services
Drug Discovery and Development
Antibody Discovery Platform
Therapeutic Area
Innovative Drug R&D
Resources
About Us
huDR3(TNFRSF25) Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
huDR3(TNFRSF25) Mouse
Product Name
huDR3(TNFRSF25) Mouse
Product ID
C002066
Strain Name
C57BL/6NCya-Tnfrsf25tm1(hTNFRSF25)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “huDR3(TNFRSF25) Mouse (Catalog C002066) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Basic Information
Related Resource
Basic Information
Gene Name
TNFRSF25
Gene Alias
DR3, TR3, DDR3, LARD, APO-3, TRAMP, WSL-1, GEF720, WSL-LR, PLEKHG5, TNFRSF12
NCBI ID
Chromosome
Chr 1 (Human)
MGI ID
Datasheet
Strain Description
Tumor necrosis factor receptor superfamily member 25 (TNFRSF25), also known as death receptor 3 (DR3), is a member of the tumor necrosis factor receptor (TNFR) superfamily and serves as the specific receptor for TNFSF15 (TL1A). It plays a critical role in immune homeostasis regulation, inflammatory responses, and apoptosis. This receptor contains a death domain and can specifically bind to its ligand TL1A. Upon binding, it recruits downstream adaptor molecules to activate NF-κB and MAPK signaling pathways, or induce apoptosis, thereby participating in the regulation of T cell proliferation and differentiation—particularly Th2 and Th17 cells—regulatory T cell (Treg) expansion, and tissue inflammatory responses [1]. TNFRSF25 is primarily expressed in lymphocyte-rich tissues, such as the spleen, thymus, and lymph nodes. It is highly expressed on the surface of activated T cells, NKT cells, and certain innate lymphoid cells, and can also be detected in mucosal tissues such as the intestine and lungs, suggesting its important role in mucosal immunity and inflammation regulation [2].
Abnormal activation of the TNFRSF25/TL1A signaling pathway is closely associated with the development of various inflammatory and autoimmune diseases, with particularly prominent roles in inflammatory bowel disease (IBD), allergic asthma, and psoriasis. Studies have shown that in inflammatory bowel disease, TNFRSF25 signaling promotes Th17 cell activation and amplifies intestinal inflammation, and is also involved in fibrosis processes. In allergic asthma, this pathway enhances Th2-type immune responses and airway inflammation [1,3]. Based on its critical role in immune regulation, TNFRSF25 has become a highly promising therapeutic target in the field of immunotherapy for inflammatory and autoimmune diseases. Anti-TL1A monoclonal antibodies have demonstrated favorable efficacy in clinical trials for IBD [4-5].
huDR3(TNFRSF25) mice are humanized models constructed using gene editing technology. In this model, the sequences from the ATG start codon to the TGA stop codon of the mouse Tnfrsf25 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFRSF25 gene. huDR3(TNFRSF25) mice can be used for preclinical studies on the pathogenesis of autoimmune and inflammatory diseases, such as inflammatory bowel disease (IBD), allergic asthma, and psoriasis, as well as for the evaluation of DR3-targeted drugs.
Reference
Fang L, Adkins B, Deyev V, Podack ER. Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation. J Exp Med. 2008;205(5):1037-1048.
Meylan F, et al. The TNF-family cytokine TL1A drives IL-13-dependent small intestinal inflammation. Mucosal Immunol. 2011;4(2):172-185.
Clarke AW, et al. An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease. MAbs. 2018;10(5):664-677.
Sands BE, et al. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis. N Engl J Med. 2024.
Feagan BG, et al. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn’s disease: a phase 2a induction trial. Lancet Gastroenterol Hepatol. 2025.
Strain Strategy
The sequences from the ATG start codon to the TGA stop codon of the mouse Tnfrsf25 gene were replaced with the sequences from the ATG start codon to the TGA stop codon of the human TNFRSF25 gene.

Figure 1. Gene editing strategy of huDR3(TNFRSF25) mice.
Application Area
The screening, development, and preclinical evaluation of TNFRSF25-targeted drugs;
Research on the pathogenesis and treatment of autoimmune diseases, such as inflammatory bowel disease (IBD), allergic asthma, and psoriasis;
Research on the mechanism of the TNFRSF25/TL1A signaling pathway.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

